Why is "Gaucher's disease" trending?

Search Interest Perspective

• Parkinson Disease Risk Evaluated in Gaucher Disease Type 1 - Neurology Advisor
• Oral Gaucher disease therapy moves ahead with help from EU status - Gaucher Disease News
• Exploring the long-term use of ambroxol in Gaucher disease type 2: insights from two pediatric cases - Frontiers
• FDA Grants Priority Review to SNY's Filing for Gaucher Disease Drug - Yahoo Finance
• Venglustat Breakthrough in Phase 3 Gaucher Disease Study - The Clinical Trial Vanguard
• Patients Treated With Spur Therapeutics’ Gaucher Disease Gene Therapy FLT201 Maintain Clinical Benefit for Up to 2 Years - CGTLive®
• The dual impact of GBA1 in disease: from germline mutations in neurological disorders to alterations in cancer - Nature
• FDA Expanded Approval of Imiglucerase Expands Treatment Options for Type 3 Gaucher Disease - Pharmacy Times
• Yuhan secures EMA orphan drug designation for Gaucher disease candidate - koreabiomed.com
• Sanofi records win and loss with rare disease drug in Phase III trials - Clinical Trials Arena
• Venglustat Improves Neurological Symptoms in Type 3 Gaucher Disease - Neurology Advisor
• Advanced heart imaging spots hidden disease risk in Gaucher early on - Gaucher Disease News
• Gene therapy may improve bone health in Gaucher disease - Gaucher Disease News
• FDA grants priority review to treatment aimed at type 3 Gaucher - Gaucher Disease News
• New mRNA therapy aims to restore missing enzyme in Gaucher: Study - Gaucher Disease News
• Venglustat named breakthrough therapy by FDA for Gaucher type 3 - Gaucher Disease News
• Gaucher biomarker changes may not mirror disease progression - Gaucher Disease News
• Bone complications affect most people with Gaucher disease, study finds - Gaucher Disease News
• Cerezyme becomes 1st FDA-approved therapy for type 3 Gaucher - Gaucher Disease News
• Cerezyme use in pregnancy tied to favorable outcomes in Gaucher study - Gaucher Disease News
• New trial data show oral venglustat beats ERT for neurological symptoms - Gaucher Disease News
• Blood cancer warning signs common in adults with Gaucher: Study - Gaucher Disease News
• Natera’s updated prenatal test now includes Gaucher disease - Gaucher Disease News
• Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease - Yahoo Finance
• As its immunology work draws attention, Sanofi also pushes forward in rare disease - STAT
• With AI and healthcare, how much information is too much? - Gaucher Disease News
• Yuhan’s Gaucher disease drug candidate granted FDA orphan drug designation - koreabiomed.com
• Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials - BioPharma Dive
• Venglustat for Gaucher disease - Gaucher Disease News
• Sanofi's troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease - Fierce Biotech
• Delivering Mental Health Care for Gaucher Disease in Egypt - Project HOPE
• Sanofi Rare Disease Drug Scores a Hit and a Miss in Phase III Tests - BioSpace
• Sanofi announces positive results for venglustat in type 3 Gaucher disease - PMLiVE
• Sanofi's genetic disorder drug shows mixed results in late-stage trials - Reuters
• Targeted, patient-oriented, preemptive, and selective screening for non-neuropathic Gaucher disease and type B acid sphingomyelinase deficiency in Polish children — a cohort study highlighting benefits for the national health system | Karwacki | Acta Haema - Via Medica Journals
• One step at a time: Going for walks is my favorite way to exercise - Gaucher Disease News
• Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study - Yahoo Finance
• Regulatory milestone for Sanofi’s venglustat in type 3 Gaucher disease - The Pharma Letter
• Yuhan’s Gaucher drug candidate wins FDA orphan status - The Korea Herald
• November date set for FDA decision on Sanofi's Gaucher drug - pharmaphorum
• Inside India’s Funding Failure in Rare Genetic Disease Care - Global Health NOW
• THX Pharma and Biocodex Announce a Strategic Licensing Agreement in Batten, Gaucher and Niemann-Pick Type C Diseases - Business Wire
• Genotype Meets Phenotype: Unraveling Gaucher’s Genetic Landscape in the Indian Population - Cureus
• Liver enlargement could be a warning sign of this rare genetic condition: What to know about Gaucher dise - The Times of India
• Type 3 Gaucher disease: brain-penetrant venglustat outperformed ERT on neurologic outcomes - Vera Health
• Fabry fizzles but Sanofi’s venglustat anchors aweigh in Gaucher - BioWorld News
• Goal of Gaucher Awareness Month 2025? A shorter diagnostic journey. - Gaucher Disease News
• Constantiam Biosciences and Cincinnati Children’s Collaborate to Accelerate First-in-Class Neuronopathic Gaucher Disease Therapies - The Manila Times
• Mixed data mars Sanofi's venglustat programme - pharmaphorum
• Sanofi’s Oral Venglustat Designated for Type 3 Gaucher Disease Neurological Issues - geneonline.com
• Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease - WebWire
• Urine bis(Monoacylglycerol)Phosphate and risk of freezing of gait in parkinson’s disease - Nature
• Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1 - The Manila Times
• Glucosylsphingosine affects mitochondrial function in a neuronal cell model | Communications Biology - Nature
• Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease - WebWire
• Yuhan wins EMA orphan status for Gaucher therapy, accelerates global trials - CHOSUNBIZ - Chosunbiz
• IHA Researchers uncover link between kidney tissue & brain health in Parkinson’s & Gaucher disease - UCL | University College London
• Yuhan Reports Phase 1 Results for Gaucher Drug YH35995 - Businesskorea
• Sanofi’s rare disease drug notches one win, one loss in a pair of Phase 3 trials - Endpoints News
• Gaucher disease provides a unique window into Parkinson disease pathogenesis - Nature
• Gaucher Disease: A Rare Disease Sheds Light on More Common Conditions - Yale Medicine
• What Is Gaucher Disease and Does it Increase Cancer Risk? - City of Hope
• Images from the Haematologica Atlas of Hematologic Cytology: Gaucher disease - Haematologica
• Classification of GBA1 variants and their impact on Parkinson’s disease: an in silico score analysis - Nature
• Upregulation of Cytotoxic T-cells in pediatric patients with Gaucher disease - Nature
• Sanofi’s Venglustat shows breakthrough results in rare neurological Gaucher disease - Indian Pharma Post
• International Gaucher Day: Rare diseases that we need to know about - Cape Times
• Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia - Nature
• High Incidence of Gaucher Disease Reported in Patients With Multiple Myeloma - Hematology Advisor
• Living on borrowed time: Tremendous cost of rare diseases in India - India Today
• Yuhan's Gaucher Disease Drug Candidate Wins EU Orphan Status After US - Seoul Economic Daily
• Study of Brain at Single-cell Resolution in Gaucher Disease Finds Key Role of Neuroinflammation - Yale School of Medicine
• Yuhan Corporation Presents Phase 1 Clinical Trial Results for Gaucher Disease Treatment at International Academic Conference - 아시아경제
• Vitreous opacities and retinal deposits in Gaucher disease type I - Nature
• Systemically delivered lipid nanoparticle-mRNA encoding lysosomal acid β-glucosidase restores the enzyme deficiency in a murine Gaucher disease model - Nature
• Lysosomal glucocerebrosidase is needed for ciliary Hedgehog signaling: A convergent pathway contributing to Parkinson’s disease - PNAS
• An increase in ER stress and unfolded protein response in iPSCs-derived neuronal cells from neuronopathic Gaucher disease patients - Nature
• New Drug Screening Funnel Could Speed New Therapies for Gaucher Disease, Parkinson's - National Center for Advancing Translational Sciences (.gov)
• Gaucher Disease: Yale Offers New Insights, Treatment, and Hope - Yale Medicine
• Neuronopathic Gaucher disease models reveal defects in cell growth promoted by Hippo pathway activation - Nature
• Case Report: Diagnosis of Gaucher disease in a toddler with acute respiratory failure - Frontiers
• Gaucher disease type 3c: Expanding the clinical spectrum of an ultra‐rare disease - Wang - 2024 - JIMD Reports - Wiley Online Library
• Nanoparticles for inducing Gaucher disease-like damage in cancer cells - Nature
• Enzyme replacement therapy in infants and very young children with Gaucher disease using velaglucerase alfa: a single-center experience - Frontiers
• Gaucher’s Disease in an Adult Male: A Case Report of a Rare Mutation - Cureus
• Exploring the efficacy and safety of Ambroxol in Gaucher disease: an overview of clinical studies - Frontiers
• Spur Therapeutics’ Gaucher Disease Gene Therapy FLT201 Continues to Show Safety and Efficacy in Phase 1/2 Trial - CGTLive®
• Gaucher’s Disease in an Adult Female: A Rare Entity - Cureus
• Gene expression profile in patients with Gaucher disease indicates activation of inflammatory processes - Nature
• Efficacy of an AAV vector encoding a thermostable form of glucocerebrosidase in alleviating symptoms in a Gaucher disease mouse model | Gene Therapy - Nature
• Old disease—New reflections: Gaucher, immunity, and inflammation - Wiley Online Library
• Five-year-old Kajiado boy who relies on lifesaving enzyme drug costing Sh1 million per month - Daily Nation
• A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin - Journal of Neuroscience
• Gene Therapy FLT201 Shows Promise in Early-Stage Study of Gaucher Disease - NeurologyLive
• Bone disease in early detected Gaucher Type I disease: A case report - Gragnaniello - 2022 - JIMD Reports - Wiley Online Library
• Involvement of hepcidin in iron metabolism dysregulation in Gaucher disease - Haematologica
• A practical synthesis of nitrone-derived C5a-functionalized isofagomines as protein stabilizers to treat Gaucher disease - Nature
• A Neonatal Case With Perinatal Lethal Gaucher Disease Associated With Missense G234E and H413P Heterozygous Mutations - Frontiers
• Disruptions in brain sphingolipid metabolism reveal new insights into cause of Gaucher disease - Baylor College of Medicine | BCM
• Screening for Gaucher Disease in Canadian Patients With Thrombocytopenia - Hematology Advisor